The Gates Foundation hoped that by 2010, scientists would have come up with a malaria vaccine that did not need refrigeration. Now it is not expected before 2015.  STEPHEN MORRISON/EUROPEAN PRESSPHOTO AGENCY
Bill Gates Reassesses His War on Disease
FIVE YEARS AGO, Bill Gates made an extraordinary offer: he invited the world’s  scientists to submit ideas for tackling the biggest problems in global health,  including the lack of vaccines for AIDS and malaria, the fact that most vaccines  must be kept refrigerated and be delivered by needles, the fact that many  tropical crops like cassavas and bananas had little nutrition, and so on. 
About  1,600 proposals came in, and the top 43 were so promising that the Bill &  Melinda Gates Foundation gave $450 million in fiveyear grants. Now the five  years are up, and the foundation recently brought all the scientists to Seattle  to assess the results. 
        
        In an interview, Mr. Gates sounded somewhat chastened,  saying several times, “We were naive when we began.”As an example, he cited  the pursuit of vaccines that do not need refrigeration. “Back then, I thought:  ‘Wow - we’ll have a bunch of thermostable vaccines by 2010.’ But we’re not  even close to that. I’d be surprised if we have even one by 2015.” 
In 2007,  instead of making more multimillion- dollar grants, he started making hundreds  of $100,000 ones. That little won’t buy a breakthrough, but it lets scientists  “moonlight” by adding goals to their existing grants. “And,” he added, “a  scientist in a developing country can do a lot with $100,000.” 
Over all, he  said, “on drawing attention to ways that lives might be saved through  scientific advances, I’d give us an A. But I thought some would be saving lives  by now, and it’ll be more like in 10 years from now.” 
What follows is a sample  of the progress of a few grants. 
Despite Gates Grants, Drive Toward a Healthier World Is Lagging
Dried Vaccines 
The hardest-hit inventors were  those working on thermostable vaccines. Several techniques worked, but paying  for all to go ahead made little sense. And having one or two heatstable ones  doesn’t help if rural clinics still need refrigerators and electricity for the  rest. 
    
    
    
    
    
Abraham L. Sonenshein of Tufts University in Massachusetts succeeded in  splicing tetanus vaccine proteins into a bacterial spore that survives heat or  cold and can be sprayed into the nose. But his grant ended before he could add  diphtheria or whooping cough vaccines or start human trials. 
Robert E. Sievers,  a University of Colorado chemist, also reached his chief goal - attaching a  measles vaccine to a sugar matrix that can be stored dry. 
Dr. Sievers’s Gates  grant is not being renewed, but he is partnering with the Serum Institute of  India. 
The foundation is still supporting two thermostabilization techniques.  The first attaches vaccines to nanoparticles that can be absorbed in the  nostrils. Dr. James R. Baker Jr., director of the University of Michigan’s  nanotechnology institute, said it works with hepatitis B and flu vaccine. 
The  second thermostabilized vaccine works against malaria. Rather than being  bottled, the vaccine can be dried onto a bit of filter paper. 
Mosquito  ‘Olfacticides’ 
As the inventors of “a cell line that behaves like a mosquito  antenna, recreating mosquito smellers in a dish,” Leslie B. Vosshall of  Rockefeller University in New York and Dr. Richard Axel, a Howard Hughes Medical  Institute investigator at Columbia University in New York, got $5 million to  hunt for molecules that could block mosquitoes’ ability to detect people. Their  Gates grant is renewed for two years. 
‘Exhausted’ Immune Cells 
Another grant  is ending because it attracted so much commercial backing. Rafi Ahmed, an  immunologist at Emory University in Atlanta, studies why the immune system’s T- cells get “exhausted” during a long battle against some viruses like H.I.V. or  hepatitis C. He discovered the cells grew “inhibitory receptors.” 
In mice and  monkeys, h e found molecules or antibodies that block those inhibitory  receptors, perking up the cells. 
“It doesn’t result in a cure, but it’s  quite promising,” said Dr. Ahmed, who hopes to find a way to revive exhausted  cells in humans with AIDS and let them take breaks from the toxic drugs. 
Because  T-cells fight many diseases, including cancer, Genentech, Bristol-Myers Squibb  and the National Institutes of Health are all offering him money. 
A Better  Banana 
James Dale of the Queensland University of Technology in Australia  successfully added Vitamin A to bananas and is working on adding iron. A new  Gates grant will support field trials in Uganda. 
Bananas are a staple for  millions of people from Africa to Ecuador to India. “They’re also one of the  best weaning foods for babies,” Dr. Dale said. “They come in a nice sterile  package and don’t need to be cooked.” 
The Ugandan government agreed to genetic  modification as long as Ugandan scientists did the work on Ugandan bananas, he  said. 
Part of the Gates grant is for “feeding trials” to see if people will  accept the new fruit, which has papaya-orange flesh from the vitamin precursor,  beta-carotene. 
And a Better Cassava 
The $7 million grant to BioCassava Plus, a  consortium led by Ohio State University, was increased to $12 million. 
While it  will take another 10 years, the project is meeting interim goals, said Richard  T. Sayre, its principal investigator. They include decreasing natural cyanide in  the tubers, increasing protein, iron, zinc and vitamins A and E, and engineering  in resistance to cassava diseases. 
Cassava is a staple for 800 million people,  but environmentalists like Greenpeace and Friends of the Earth have slowed the  project by opposing field trials in Nigeria and Uganda. 
Mosquitoes and Bacteria  
The fastest-moving project is that of Scott O’Neill, a biologist at the  University of Queensland, Australia. 
Five years ago, Dr. O’Neill got $7 million  to try to infect mosquitoes with a strain of wolbachia bacteria that didn’t  kill mosquitoes outright, but made them die before they got old. 
The advantage  is that a female must be “middle-aged” - about 14 days - before she can pick  up the dengue fever virus from one human, see it mature in her gut and then pass  it on to another human. The wolbachia strain Dr. O’Neill used had an unexpected  side effect: it also blocked chikungunya, another disease. 
“That turned  everything on its head for us,” he said. “It’s like a vaccine for mosquitoes - it protects them from picking up the virus.” 
The Gates Foundation is still  supporting his work. 
Stem Cells to Muscles 
The most radical project announced in  2005 was that of Dr. David Baltimore, who shared a 1975 Nobel Prize in Medicine.  Dr. Baltimore envisioned removing stem cells destined to be white blood cells  from people and infecting them with a slow-acting virus containing genes to  reprogram their internal machinery to produce double- headed antibodies to  attack H.I.V. at two different points. 
“This original high-risk, high-reward  approach proved too difficult,” said a foundation document . The grant was  “repurposed” with a different goal: to inject genes that code for these new  antibodies into muscle cells. The hope is that this could become a simpler form  of prevention than current H.I.V. vaccine efforts.
By DONALD G. McNEIL Jr.                
               
                 
                                
            
 
            	
            
댓글 안에 당신의 성숙함도 담아 주세요.
'오늘의 한마디'는 기사에 대하여 자신의 생각을 말하고 남의 생각을 들으며 서로 다양한 의견을 나누는 공간입니다. 그러나 간혹 불건전한 내용을 올리시는 분들이 계셔서 건전한 인터넷문화 정착을 위해 아래와 같은 운영원칙을 적용합니다.
자체 모니터링을 통해 아래에 해당하는 내용이 포함된 댓글이 발견되면 예고없이 삭제 조치를 하겠습니다.
불건전한 댓글을 올리거나, 이름에 비속어 및 상대방의 불쾌감을 주는 단어를 사용, 유명인 또는 특정 일반인을 사칭하는 경우 이용에 대한 차단 제재를 받을 수 있습니다. 차단될 경우, 일주일간 댓글을 달수 없게 됩니다.
명예훼손, 개인정보 유출, 욕설 등 법률에 위반되는 댓글은 관계 법령에 의거 민형사상 처벌을 받을 수 있으니 이용에 주의를 부탁드립니다.
Close
x